Gemtuzumab ozogamicin (TP-107CL)
Recombinant humanized IgG4, kappa antibody conjugated with a cytotoxic antitumor antibiotic, calicheamicin, isolated from fermentation of a bacterium, Micromonospora echinospora ssp. calichensis. The antibody portion of Mylotarg binds specifically to the CD33 antigen, The anti-CD33 hP67.6 antibody is produced by mammalian cell suspension culture using a myeloma NS0 cell line. Gemtuzumab ozogamicin (trade name Mylotarg) was withdrawn in 2010 when a clinical trial showed the drug increased patient death and exhibited no advantages over traditional cancer therapies.
Specifications
- Classify
- Protein therapeutics that deliver other compounds or proteins
- Therapeutic
- Gemtuzumab ozogamicin
- Trade Name
- Mylotarg
- Function
- Humanized anti-CD33 IgG4k mAb conjugated to calicheamicin, a small-molecule chemotherapeutic agent
- Examples of Clinical Use
- Relapsed CD33+ acute myeloid leukaemia in patients who are more than 60 years old and are not candidates for cytotoxic chemotherapy
References
- Synonyms
- Not Available
For lab research use only, not for diagnostic, therapeutic or any in vivo human use.
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
Tel: 1-631-381-2994
Fax: 1-631-207-8356
Email: